Key Highlights

  • Total third-quarter Revenue at Nuvation Bio (NYSE:NUVB) reached USD 45.0 million, roughly triple the USD 13.1 million of a year earlier, and IBTROZI contributed USD 27.5 million of that figure.
  • Net loss contracted to USD 41.9 million (USD 0.12 a share) from USD 55.8 million (USD 0.16), and the nine-month loss totaled USD 99.3 million, down from USD 168.0 million.
  • Income from collaborations and licenses grew to USD 17.5 million from USD 5.4 million, with Innovent's sales-based milestone of USD 5.0 million and USD 7.6 million of extra Supply revenue as factors.
  • In management's view, the USD 663.4 million of cash and marketable securities held on September 30, 2026 is sufficient for operating and Capital needs over a minimum of 12 months.

IBTROZI Launch Pushes Revenue Above USD 45 Million

IBTROZI, approved for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, generated USD 27.5 million of U.S. net product revenue this quarter, compared with USD 7.7 million in the third quarter of 2025. Nine-month IBTROZI sales were USD 69.2 million, up from USD 9.0 million. The U.S. launch came in June 2025, following FDA approval granted June 11, 2025, which explains the modest comparison base. Revenue for nine months totaled USD 159.9 million, against USD 21.0 million, lifted by a license payment from a new collaborator.

Eisai Partnership, Label Expansion and Pipeline Designations

Early in 2026, an agreement with Eisai was struck to market taletrectinib, IBTROZI's active ingredient, across Europe and other regions excluding the U.S., China and Japan. The upfront payment raised nine-month license revenue by USD 58.7 million. The European Medicines Agency validated the Marketing authorization application in March 2026. In September 2026 the FDA approved a label update that reflects a median duration of response of 49.7 months among treatment-naive patients in the TRUST-I study. In August 2026 the FDA granted Fast Track Designation to safusidenib, an investigational brain-penetrant mutant IDH1 inhibitor tested in glioma and astrocytoma. Royalty revenue increased USD 2.4 million in the quarter, while Research and Development service revenue declined USD 2.9 million.

Ongoing Losses Set Against USD 663.4 Million in Cash

Cost of sales increased to USD 2.1 million from USD 0.3 million as IBTROZI volumes grew. The company has booked a net loss in every year since its founding and carries an accumulated Deficit of USD 1,214.7 million. It expects expenses to climb as trials advance, approvals are pursued and commercial operations expand, and it says substantial additional funding will be needed over time through equity, debt, grants or collaborations if product revenue falls short. Partnership-based funding could require surrendering rights to products or technology. The filing provides no numerical guidance, consensus figure or price move. Confirmatory and adjuvant studies, including TRUST-III and TRUST-IV for taletrectinib, are still underway.

Where Things Stand

The loss is narrowing, but the pace depends on IBTROZI sales and partner payments. Nuvation Bio (NYSE:NUVB) cut its quarterly loss to USD 41.9 million as product revenue more than tripled, and USD 663.4 million of cash and securities covers roughly a year of needs by the company's own estimate. On the other side, one-time license income inflates the nine-month comparison, and costs are expected to rise. Watch IBTROZI sales growth, the European review, the safusidenib program and any new financing signals.